Soluble elastin peptides in cardiovascular homeostasis: Foe or ally

Zhenyu Qin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Elastin peptides, also known as elastin-derived peptides or elastokines, are soluble polypeptides in blood and tissue. The blood levels of elastin peptides are usually low but can increase during cardiovascular diseases, such as atherosclerosis, aortic aneurysm and diabetes with vascular complications. Generally, elastin peptides are derived from the degradation of insoluble elastic polymers. The biological activities of elastin peptides are bidirectional, e.g., a pro-inflammatory effect on monocyte migration induction vs. a protective effect on vasodilation promotion. However, recent in vivo studies have demonstrated that elastin peptides promote the formation of atherosclerotic plaques in hypercholesterolemic mice and induce hyperglycemia and elevations in plasma lipid levels in fasted mice. More important, the detrimental effects induced by elastin peptides can be largely inhibited by genetic or pharmacological blockade of the elastin receptor complex or by neutralization of an antibody against elastin peptides. These studies indicate new therapeutic strategies for the treatment of cardiovascular diseases by targeting elastin peptide metabolism. Therefore, the goal of this review is to summarize current knowledge about elastin peptides relevant to cardiovascular pathologies to further delineate their potential application in cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)64-73
Number of pages10
JournalPeptides
Volume67
DOIs
StatePublished - May 1 2015

Fingerprint

Elastin
Homeostasis
Peptides
Cardiovascular Diseases
metsulfuron methyl
Blood
Aortic Aneurysm
Pathology
Atherosclerotic Plaques
Medical problems
Bioactivity
Metabolism
Vasodilation
Hyperglycemia
Blood Vessels
Monocytes
Atherosclerosis
Polymers
Pharmacology
Tissue

Keywords

  • Cardiovascular diseases
  • Elastin
  • Peptide

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Soluble elastin peptides in cardiovascular homeostasis : Foe or ally. / Qin, Zhenyu.

In: Peptides, Vol. 67, 01.05.2015, p. 64-73.

Research output: Contribution to journalArticle

@article{9ced9bf1e4e64333a3810f091d9301eb,
title = "Soluble elastin peptides in cardiovascular homeostasis: Foe or ally",
abstract = "Elastin peptides, also known as elastin-derived peptides or elastokines, are soluble polypeptides in blood and tissue. The blood levels of elastin peptides are usually low but can increase during cardiovascular diseases, such as atherosclerosis, aortic aneurysm and diabetes with vascular complications. Generally, elastin peptides are derived from the degradation of insoluble elastic polymers. The biological activities of elastin peptides are bidirectional, e.g., a pro-inflammatory effect on monocyte migration induction vs. a protective effect on vasodilation promotion. However, recent in vivo studies have demonstrated that elastin peptides promote the formation of atherosclerotic plaques in hypercholesterolemic mice and induce hyperglycemia and elevations in plasma lipid levels in fasted mice. More important, the detrimental effects induced by elastin peptides can be largely inhibited by genetic or pharmacological blockade of the elastin receptor complex or by neutralization of an antibody against elastin peptides. These studies indicate new therapeutic strategies for the treatment of cardiovascular diseases by targeting elastin peptide metabolism. Therefore, the goal of this review is to summarize current knowledge about elastin peptides relevant to cardiovascular pathologies to further delineate their potential application in cardiovascular disease.",
keywords = "Cardiovascular diseases, Elastin, Peptide",
author = "Zhenyu Qin",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.peptides.2015.03.006",
language = "English (US)",
volume = "67",
pages = "64--73",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Soluble elastin peptides in cardiovascular homeostasis

T2 - Foe or ally

AU - Qin, Zhenyu

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Elastin peptides, also known as elastin-derived peptides or elastokines, are soluble polypeptides in blood and tissue. The blood levels of elastin peptides are usually low but can increase during cardiovascular diseases, such as atherosclerosis, aortic aneurysm and diabetes with vascular complications. Generally, elastin peptides are derived from the degradation of insoluble elastic polymers. The biological activities of elastin peptides are bidirectional, e.g., a pro-inflammatory effect on monocyte migration induction vs. a protective effect on vasodilation promotion. However, recent in vivo studies have demonstrated that elastin peptides promote the formation of atherosclerotic plaques in hypercholesterolemic mice and induce hyperglycemia and elevations in plasma lipid levels in fasted mice. More important, the detrimental effects induced by elastin peptides can be largely inhibited by genetic or pharmacological blockade of the elastin receptor complex or by neutralization of an antibody against elastin peptides. These studies indicate new therapeutic strategies for the treatment of cardiovascular diseases by targeting elastin peptide metabolism. Therefore, the goal of this review is to summarize current knowledge about elastin peptides relevant to cardiovascular pathologies to further delineate their potential application in cardiovascular disease.

AB - Elastin peptides, also known as elastin-derived peptides or elastokines, are soluble polypeptides in blood and tissue. The blood levels of elastin peptides are usually low but can increase during cardiovascular diseases, such as atherosclerosis, aortic aneurysm and diabetes with vascular complications. Generally, elastin peptides are derived from the degradation of insoluble elastic polymers. The biological activities of elastin peptides are bidirectional, e.g., a pro-inflammatory effect on monocyte migration induction vs. a protective effect on vasodilation promotion. However, recent in vivo studies have demonstrated that elastin peptides promote the formation of atherosclerotic plaques in hypercholesterolemic mice and induce hyperglycemia and elevations in plasma lipid levels in fasted mice. More important, the detrimental effects induced by elastin peptides can be largely inhibited by genetic or pharmacological blockade of the elastin receptor complex or by neutralization of an antibody against elastin peptides. These studies indicate new therapeutic strategies for the treatment of cardiovascular diseases by targeting elastin peptide metabolism. Therefore, the goal of this review is to summarize current knowledge about elastin peptides relevant to cardiovascular pathologies to further delineate their potential application in cardiovascular disease.

KW - Cardiovascular diseases

KW - Elastin

KW - Peptide

UR - http://www.scopus.com/inward/record.url?scp=84926466931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926466931&partnerID=8YFLogxK

U2 - 10.1016/j.peptides.2015.03.006

DO - 10.1016/j.peptides.2015.03.006

M3 - Article

C2 - 25794852

AN - SCOPUS:84926466931

VL - 67

SP - 64

EP - 73

JO - Peptides

JF - Peptides

SN - 0196-9781

ER -